Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20719544 | 0.81 | KDM4E (0.34) | NPC1KDM4EALDH1A1TSHRPDE4D | |
| SCHEMBL25716137 | 0.78 | GRM2 (0.38) | ALDH1A1MAT2A | |
| SCHEMBL22804587 | 0.78 | PDE4D (0.41) | LMNAKDM4EALDH1A1TSHRPDE4D | |
| SCHEMBL15910912 | 0.78 | NQO2 (0.39) | NPC1RAB9ALMNAKDM4EALDH1A1 | |
| SCHEMBL16722440 | 0.77 | ALDH1A1 (0.39) | MAPTKDM4EALDH1A1 | |
| SCHEMBL5076661 | 0.77 | ADORA3 (0.40) | LMNAMAPT | |
| SCHEMBL22912925 | 0.75 | PARK7 (0.41) | NPC1RAB9ALMNAMAPTKDM4E | |
| SCHEMBL17682469 | 0.72 | AR (0.39) | NPC1RAB9ALMNAMAPTKDM4E | |
| SCHEMBL2588229 | 0.72 | KDM4E (0.46) | NPC1RAB9ALMNAMAPTKDM4E | |
| SCHEMBL25103763 | 0.70 | NPC1 (0.39) | NPC1RAB9ALMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-17 | — | — | US | disclosed |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | disclosed |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | disclosed |
| EP-3055300-B1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9278953-B2 | Antagonists of prostaglandin EP3 receptor | PFIZER INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PFIZER INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | NPC1 3947/4885RAB9A 3989/4885LMNA 1335/4885 |
| US-10590083-B2 | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | NPC1 3824/4885RAB9A 3974/4885LMNA 1286/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | NPC1 3947/4885RAB9A 3989/4885LMNA 1335/4885 |
| US-20150099782-A1 | ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR | PTGER3, PTGES3, PTGER2 | NPC1 3292/4885RAB9A 4234/4885LMNA 2327/4885 |
| US-20190047959-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | NPC1 3824/4885RAB9A 3974/4885LMNA 1286/4885 |
| US-10399944-B2 | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | NPC1 3967/4885RAB9A 3861/4885LMNA 1291/4885 |
| US-20190047961-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | NPC1 3967/4885RAB9A 3861/4885LMNA 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.